Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPolar Capital Regulatory News (POLR)

Share Price Information for Polar Capital (POLR)

Share Price is delayed by 15 minutes
Get Live Data
820.00    -11.00 (-1.32%)
Bid:
816.00
Ask:
822.00
Spread: 6.00 (0.735%)
Market Cap: £774.61m
POLR Live PriceLast checked at - London Stock Exchange

Intraday Polar Capital Share Chart

AuM Update

9 Jan 2020 07:00

RNS Number : 2064Z
Polar Capital Holdings PLC
09 January 2020
 

9 January 2020 Polar Capital Holdings plc

AuM Update

 

 

Polar Capital Holdings plc ("Polar Capital" or the "Group"), the specialist active asset management group, today provides its regular quarterly update of its unaudited statement of its Assets under Management ("AUM") and performance fees earned for the calendar year to 31 December 2019.

 

Group AUM (unaudited)

 

Polar Capital reports that as at 31 December 2019 its AuM were £14.2bn compared to £13.8bn at the end of March 2019, an increase of 3% over the period. During the period, AuM increased by £0.4bn which comprised net outflows of £1.1bn offset by an increase of £1.5bn related to market movement and fund performance.

 

AuM movement in nine months to 31 December 2019

Long-only

funds

Alternative funds

Total

AuM at

1 April 2019

£12,529m

£1,306m

£13,835m

Net subscriptions

£(1,132)m

£61m

£(1,071)m

Market movement

and performance

£1,397m

£60m

£1,457m

Total AuM at

31 December 2019

£12,794m

£1,427m

£14,221m

 

Net performance fees (unaudited)

 

The table below sets out the position relating to net performance fee profits (after the deduction of staff interests) earned in the first nine months of the Group's financial year.

 

Performance fee profit

net of staff allocations

Nine months to

31 Dec 18

Year to

31 Mar 19

(year-end)

Nine months to

31 Dec 19*

Net performance fee profit

£23.6m

£24.0m

£8.8m*

 

\* The figures to December 2019 are reduced by what is expected to be circa £1.4m of net deferment that IFRS requires to be deducted from this year's receipts.

 

 

Gavin Rochussen, Chief Executive, commented:

 

"Although AuM in the nine months has increased by £400m from £13.8bn to £14.2bn, it has been another challenging quarter. Net outflows of £623m were offset by an increase in AuM of £542m from market and performance movements resulting in a decline in AuM in the quarter of £81m.

 

"The election result and reduced Brexit uncertainty increased demand for our UK Value Fund which had net inflows of £100m in December. On the other hand, clients continued to reduce their exposure to North American equities. This led to net outflows from our North American Fund of £611m in the quarter, which includes the reallocation of a client mandate away from North American equities to alternative asset classes.

 

"The Japan Value Fund continued to perform well and had net inflows in December of £48m marking an end to multi-year monthly outflows from our Japan funds.

 

"In the nine month period to 31 December we were not immune to the challenging conditions experienced by the industry as a whole; total net outflows amounted to £1.1bn which was dominated by net outflows of £453m from the Japan Fund prior to the merger with the Japan Value Fund, net outflows from our North American strategy of £795m and an aggregate £500m redemption by a long-standing client in our Technology and Healthcare Funds.

 

"It is pleasing to report net inflows over the nine months into the majority of our Funds including Global Technology, Japan Value, UK Value Opportunities, GEM Stars, Asia and China Stars, Global Insurance, European ex-UK Income, Global Convertible Bonds, Global (Convertibles) Absolute Return, UK Absolute Equity and China Mercury.

 

"Fund performance across the range of our funds was strong in the last quarter of the calendar year resulting in crystallised net performance fee profits of £8.8m for the period to 31 December.

 

"Over three years annualised, 67% of our Funds and 81% of AuM have outperformed their respective benchmarks.

 

"We have a diverse and complementary range of fund strategies with proven track records. We remain confident that, over the long term, our active fundamental strategies will continue to deliver above average returns for our clients and compelling total returns for our shareholders."

 

 

 

For further information please contact:

 

Polar Capital

Gavin Rochussen (Chief Executive)

John Mansell (Executive Director)

Samir Ayub (Finance Director)

 

+44 (0)20 7227 2700

Numis Securities Limited - Nomad and Joint Broker

Charles Farquhar

Stephen Westgate

Kevin Cruickshank (QE)

+44 (0)20 7260 1000

 

 

Peel Hunt LLP - Joint Broker

Guy Wiehahn

Andrew Buchanan

 

+44 (0)20 7418 8893

 

Camarco

Ed Gascoigne-Pees

Monique Perks

 

+44 (0)20 3757 4995

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTEAKFPELSEEFA
Date   Source Headline
19th Mar 202012:03 pmRNSPrice Monitoring Extension
12th Mar 20208:37 amRNSIssue of Equity
2nd Mar 20207:00 amRNSTotal Voting Rights
28th Feb 20204:41 pmRNSSecond Price Monitoring Extn
28th Feb 20204:36 pmRNSPrice Monitoring Extension
21st Feb 202011:51 amRNSForm 8.3 - Redde PLC
21st Feb 20209:59 amRNSIssue of Equity
20th Feb 20201:54 pmRNSForm 8.3 - Redde PLC
18th Feb 202011:14 amRNSForm 8.3 - Redde PLC
18th Feb 202010:28 amRNSChange of Auditor
17th Feb 20202:44 pmRNSForm 8.3 - Redde PLC
13th Feb 20202:37 pmRNSIssue of Equity
13th Feb 20207:00 amRNSTeam Acquisition
7th Feb 20201:09 pmRNSForm 8.3 - Redde PLC
6th Feb 20202:45 pmRNSForm 8.3 - Redde PLC
5th Feb 20202:33 pmRNSForm 8.3 - Redde PLC
3rd Feb 202011:14 amRNSBlock listing Interim Review
28th Jan 20201:06 pmRNSForm 8.3 - Redde PLC
22nd Jan 202011:13 amRNSForm 8.3 - Consort Medical PLC
21st Jan 20202:26 pmRNSForm 8.3 - Redde PLC
21st Jan 20202:12 pmRNSForm 8.3 - Consort Medical PLC
20th Jan 20202:01 pmRNSForm 8.3 - Consort Medical PLC
20th Jan 20201:37 pmRNSForm 8.3 - Redde PLC
17th Jan 202011:13 amRNSForm 8.3 - Redde PLC
17th Jan 202011:13 amRNSForm 8.3 - Consort Medical PLC
16th Jan 202012:28 pmRNSForm 8.3 - Redde PLC
16th Jan 202012:26 pmRNSForm 8.3 - Consort Medical PLC
15th Jan 202012:20 pmRNSForm 8.3 - Redde PLC
14th Jan 202012:00 pmRNSForm 8.3 - Redde PLC
13th Jan 20201:49 pmRNSForm 8.3 - Redde Plc
10th Jan 20201:09 pmRNSForm 8.3 - Redde Plc
9th Jan 20207:00 amRNSAuM Update
30th Dec 201912:35 pmRNSForm 8.3 - Redde PLC
24th Dec 201911:35 amRNSForm 8.3 - Redde PLC
23rd Dec 20193:24 pmRNSForm 8.3 - Redde PLC
20th Dec 201911:18 amRNSForm 8.3 - Redde PLC
19th Dec 20192:17 pmRNSForm 8.3 - Redde PLC
18th Dec 20191:42 pmRNSForm 8.3 - Consort Medical PLC
17th Dec 201910:58 amRNSForm 8.3 - Consort Medical Plc
17th Dec 20199:37 amRNSHolding(s) in Company
6th Dec 20191:09 pmRNSForm 8.3 - Consort Medical Plc
5th Dec 20192:24 pmRNSForm 8.3 - Consort Medical Plc
4th Dec 20191:22 pmRNSForm 8.3 - Consort Medical Plc
2nd Dec 20191:59 pmRNSForm 8.3 - Redde PLC
2nd Dec 20197:00 amRNSTotal Voting Rights
25th Nov 20197:00 amRNSUnaudited interim results
20th Nov 20194:40 pmRNSSecond Price Monitoring Extn
20th Nov 20194:35 pmRNSPrice Monitoring Extension
20th Nov 20191:52 pmRNSBlock Listing Application
20th Nov 20191:30 pmRNSCrystallisation of Business Unit & Issue of Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.